In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5 % of trial subjects receiving valsartan and 19.0 % of those receiving a thiazide diuretic experienced cough compared to 68.5 % of those treated with an ACE inhibitor (P < 0.05).
V kliničnem preskušanju pri bolnikih, ki so imeli v anamnezi suh kašelj v času zdravljenja z zaviralcem ACE, je do kašlja prišlo pri 19, 5 % preiskovancev, ki so dobivali valsartan, pri 19, 0 % tistih, ki so prejemali tiazidni diuretik, in pri 68, 5 % preiskovancev, ki so dobivali zaviralec ACE (p < 0, 05).